Skip to main content
. 2022 Jan 11;7:11. [Version 1] doi: 10.12688/wellcomeopenres.16986.1

Figure 2. Anti-TNF (tumour necrosis factor) therapy in patients with NPC1 genetic defect and Crohn’s disease (CD).

Figure 2.

The grey shaded area represents time from age of IBD diagnosis to age at most recent follow up data. Red line represents duration of infliximab therapy with green line representing adalimumab therapy. IBD=inflammatory bowel disease.